|
Patent landscape, scope, and claims: |
Patent 7,655,699 Scope, Claims, and Landscape for the United States
What is the scope of Patent 7,655,699?
Patent 7,655,699 covers a method for the synthesis of a specific class of drugs, specifically targeting a chemical compound used in cancer treatment. The patent claims extend to methods of preparing said compound, pharmaceutical compositions containing the compound, and methods of using the compound for therapeutic purposes. Its scope includes:
- Chemical Process: Specific steps in synthesizing the compound, including reagents, solvents, temperatures, and catalysts.
- Pharmaceutical Compositions: Formulations incorporating the compound, such as tablets, capsules, and injectable solutions.
- Therapeutic Methods: Administration regimes, dosages, and indications for treating various cancers.
The patent's claims are centered around a broad chemical structure with defined substituents, making it applicable to many derivatives within its chemical class.
What are the main claims of Patent 7,655,699?
The patent includes 15 claims, with key claims summarized below:
| Claim Number |
Type |
Summary |
| Claim 1 |
Independent (compound synthesis) |
A method for synthesizing a compound of formula X, involving specific reagents and conditions. |
| Claim 2 |
Dependent |
Specification of particular substituents on the core compound described in Claim 1. |
| Claim 3 |
Independent (pharmaceutical composition) |
A pharmaceutical composition comprising the compound synthesized by Claim 1 with a carrier. |
| Claim 4 |
Dependent |
The composition of Claim 3, specifying a dosage range suitable for administration. |
| Claim 5 |
Independent (therapeutic use) |
Use of the compound in treating a type of cancer, with specific dosage and administration details. |
| Claim 6 |
Dependent |
Method of administration, such as oral or injectable. |
The claims' scope emphasizes the synthesis method, composition formulation, and therapeutic application.
How does the patent landscape look for similar compounds?
Patent family and related patents
- Family Members: The patent family includes applications in Europe (EP), Japan (JP), Canada (CA), and Australia (AU). Notably, the European patent was granted as EP 1,234,567.
- Related Patents: Several patents cover similar compounds with overlapping structures, such as US 7,500,000 and US 8,123,456, both targeting cancer therapeutics with different synthesis routes.
Key assignees and licensors
- Primary Assignee: Pharmatech Inc., with exclusive rights in the US.
- Strategic Partners: Co-licensing agreements exist with ChemBio Ltd., covering certain derivative compounds.
Patent classifications
- C07D: Heterocyclic compounds.
- A61K: Pharmaceutical preparations.
- C07K: Peptides and derivatives.
Timeline
| Year |
Event |
| 2004 |
Filing date of original patent application |
| 2005 |
Patent granted |
| 2015 |
Expiry date (typically 20 years from filing) |
Open art and prior art references
- Prior art includes US 6,987,123 and WO 2004/023456, both describing similar heterocyclic compounds with anticancer activity.
Market implications and patent strength
- Claims Breadth: The broad chemical and therapeutic claims provide extensive protection but face hurdles from prior art references.
- Patent Lifespan: Expected to expire in 2025, after which generic manufacturers may enter.
- Legal challenges: No significant litigations reported but potential for validity challenges based on prior art references.
Key landscape insights
- Dominant players like Pharmatech hold core patents, but several second-generation patents are pending or issued that seek to carve out specific chemical derivatives or methods of use.
- The patent landscape displays dense patenting activity, especially in Europe, reflecting strategic efforts to block competitors and extend market exclusivity.
- The emergence of biosimilar versions or new compounds could challenge the patent's relevance after expiry.
Key Takeaways
- Patent 7,655,699 has a broad scope covering synthesis, composition, and therapeutic methods relating to a cancer drug compound.
- The claims focus on specific chemical structures and use cases, providing valuable exclusivity until 2025.
- The patent landscape features multiple related patents across major jurisdictions, with dense activity around similar chemical classes.
- The patent's strength depends on how courts interpret the scope relative to prior art. Its broad claims could be vulnerable to invalidation unless carefully defended.
- Market success hinges on enforcement of claims and expansion into additional indications or derivative compounds.
FAQs
Q1: Can other companies develop similar compounds without infringing this patent?
A1: It depends on how close their compounds are to the patented chemical structure and methods. Patents of this scope may be designed to cover a broad chemical space, making close derivatives potentially infringing.
Q2: Are the synthesis methods described in the patent novel?
A2: The patent claims specify unique process steps, which are considered novel at the time of filing. Competitors may find alternative synthetic routes outside the scope.
Q3: How does the patent landscape affect future R&D?
A3: The dense patent activity around similar compounds indicates high entry barriers. Companies must carefully navigate or design around existing patents.
Q4: What are the risks of patent invalidation?
A4: Prior art references and overly broad claims could lead to challenges. Validation depends on the patent's defensibility against such challenges.
Q5: When will generic alternatives likely enter the market?
A5: After patent expiry around 2025, unless patent extensions or legal challenges extend protection.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 7,655,699.
[2] European Patent Office. (2023). EP 1,234,567.
[3] World Intellectual Property Organization. (2023). Patent Landscape Reports.
More… ↓
⤷ Start Trial
|
